Theseus Pharmaceuticals, Inc. (THRX)

Feb 14, 2024 - THRX was delisted (reason: acquired by Concentra Biosciences)
4.060
0.00 (0.00%)
Last trade price

Theseus Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 2022202120202019
Selling, General & Admin
18.399.010.880.82
Research & Development
35.718.335.964.12
Operating Expenses
54.0927.346.844.94
Operating Income
-54.09-27.34-6.84-4.94
Other Expense / Income
-3.48-0.035.162.24
Pretax Income
-50.61-27.31-12-7.18
Net Income
-50.61-27.31-12-7.18
Shares Outstanding (Basic)
381010
Shares Outstanding (Diluted)
381010
Shares Change
299.61%1594.35%257.58%-
EPS (Basic)
-1.31-2.84-21.10-45.18
EPS (Diluted)
-1.31-2.84-21.10-45.18
Free Cash Flow
-33.4-27.19-4.85-4.81
Free Cash Flow Per Share
-0.87-2.82-8.54-30.24
EBITDA
-50.17-27.31-12-7.18
Depreciation & Amortization
0.44000
EBIT
-50.61-27.31-12-7.18
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).